中国实用医刊
中國實用醫刊
중국실용의간
CENTRAL PLAINS MEDICAL JOURNAL
2012年
3期
43-45
,共3页
2型糖尿病%吡格列酮%氧化低密度脂蛋白%动脉粥样硬化
2型糖尿病%吡格列酮%氧化低密度脂蛋白%動脈粥樣硬化
2형당뇨병%필격렬동%양화저밀도지단백%동맥죽양경화
Type 2 dibetes mellitus%Pioglitazone%Oxidized low-density lipoproteins( OXLDL)%Artherosclerosis
目的 观察吡格列酮对2型糖尿病患者氧化低密度脂蛋白(OXLDL)的影响并探讨其可能的发生机制.方法 选择符合WHO 1999年诊断标准的2型糖尿病患者65例,随机分成治疗组(33例)和对照组(32例).治疗组降糖药物选用胰岛素或磺脲类+吡格列酮,对照组仅用胰岛素或磺脲类控制血糖,其他常规治疗药物中不使用二甲双胍、血管转换酶抑制剂、阿斯匹林、他汀类、维生素C、维生素E等药物.疗程6个月.所有患者治疗前后均于清晨空腹抽血留取标本,用于氧化低密度脂蛋白(OXLDL)的测定.结果 65例患者共有61例完成了本观察,两组患者治疗后OXLDL较治疗前明显降低(P均＜0.05)；治疗后治疗组OXLDL下降水平明显高于对照组(P＜0.O1).治疗中无一例患者出现明显不良反应.结论 吡格列酮除具有降血糖作用,同样具有降低糖尿病患者血中OXLDL水平,改善2型糖尿病患者抗动脉粥样硬化的能力.
目的 觀察吡格列酮對2型糖尿病患者氧化低密度脂蛋白(OXLDL)的影響併探討其可能的髮生機製.方法 選擇符閤WHO 1999年診斷標準的2型糖尿病患者65例,隨機分成治療組(33例)和對照組(32例).治療組降糖藥物選用胰島素或磺脲類+吡格列酮,對照組僅用胰島素或磺脲類控製血糖,其他常規治療藥物中不使用二甲雙胍、血管轉換酶抑製劑、阿斯匹林、他汀類、維生素C、維生素E等藥物.療程6箇月.所有患者治療前後均于清晨空腹抽血留取標本,用于氧化低密度脂蛋白(OXLDL)的測定.結果 65例患者共有61例完成瞭本觀察,兩組患者治療後OXLDL較治療前明顯降低(P均＜0.05)；治療後治療組OXLDL下降水平明顯高于對照組(P＜0.O1).治療中無一例患者齣現明顯不良反應.結論 吡格列酮除具有降血糖作用,同樣具有降低糖尿病患者血中OXLDL水平,改善2型糖尿病患者抗動脈粥樣硬化的能力.
목적 관찰필격렬동대2형당뇨병환자양화저밀도지단백(OXLDL)적영향병탐토기가능적발생궤제.방법 선택부합WHO 1999년진단표준적2형당뇨병환자65례,수궤분성치료조(33례)화대조조(32례).치료조강당약물선용이도소혹광뇨류+필격렬동,대조조부용이도소혹광뇨류공제혈당,기타상규치료약물중불사용이갑쌍고、혈관전환매억제제、아사필림、타정류、유생소C、유생소E등약물.료정6개월.소유환자치료전후균우청신공복추혈류취표본,용우양화저밀도지단백(OXLDL)적측정.결과 65례환자공유61례완성료본관찰,량조환자치료후OXLDL교치료전명현강저(P균＜0.05)；치료후치료조OXLDL하강수평명현고우대조조(P＜0.O1).치료중무일례환자출현명현불량반응.결론 필격렬동제구유강혈당작용,동양구유강저당뇨병환자혈중OXLDL수평,개선2형당뇨병환자항동맥죽양경화적능력.
Objective To observe the effect of pioglitazone on oxidized low-density lipoproteins (OXLDL) in type 2 diabetes patients and investigate the possible mechanism.Methods Sixty-five patients with type 2 diabetes mellitus who in accord with diagnostic criteria of WH0 1990 were randomly divided into therapy group ( n =33) and control group ( n =32).Choose insulin or sulphanylureas with or without pioglitazone as therapy drug The therapy course was 6 months.Changes of OXLDL of fasting blood were observed in the therapy group and the control group before and after the trial.Results Sixty-one cases completed this obervation.The level of OXLDL of fasting blood decreased obviously after treatment both in therapy group and control group( all P ＜ 0.05).The level of OXLDL of fasting blood of therapy group decreased more obviously than control group after treatment( (P ＜ 0.01).There was no patient with obviously adverse reaction.Conclusions Pioglitazone has the effect of hypoglycemia and decrease serum OXLDL level,improve the antiartherosclerosis ability of type 2 diabetes mellitus patients.
